|
| Press Releases |
|
 |
|
| Monday, May 16, 2016 |
|
|
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. more info >> |
|
| Thursday, April 14, 2016 |
|
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016. more info >> |
|
|
Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options |
| Eisai Co., Ltd. ("the Company") today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"). more info >> |
|
| Tuesday, March 29, 2016 |
|
|
Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan |
| Eisai Co., Ltd. announced today that its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) has been approved in Japan as an adjunctive therapy for partial-onset seizures or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs. more info >> |
|
| Tuesday, March 22, 2016 |
|
|
Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan. more info >> |
|
| Thursday, March 17, 2016 |
|
|
Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym |
| Eisai Co., Ltd. announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's meeting held on March 17 regarding the egg white lysozyme preparation Neuzym (lysozyme hydrochloride, "lysozyme") which had been submitted for reevaluation. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MHI Is Awarded Contract for 20 Units of the Outer Vertical Target for the Divertor Used in the ITER in Southern France
Sept 18, 2025 0:16 JST
|
|
|
NTT and Mitsubishi Heavy Industries Achieved World's Highest Efficiency in Laser Wireless Power Transmission under Atmospheric Turbulence
Sept 18, 2025 0:00 JST
|
|
|
Galaxy Payroll Group Limited Granted Additional 180-Day Compliance Period by Nasdaq to Regain Minimum Bid Price Requirement
Sept 18, 2025 22:30 HKT/SGT
|
|
|
CGSI Reiterates 'Add' Rating on Modern Dental (03600.HK) with Raised Target Price of HK$6.88
Sept 18, 2025 16:30 HKT/SGT
|
|
|
Counterfeit Products Sold Online in Malaysia Threaten Halal Compliance, Consumer Health, and the E-Commerce Sector, Says Muslim Consumers Association (PPIM)
Sept 18, 2025 13:20 HKT/SGT
|
|
|
Dongwu Cement (00695.HK) Undergoes Major Transformation with Suzhou State Capital Takeover
Sept 18, 2025 08:30 HKT/SGT
|
|
|
GMG Launches First to Market Multi Language Global Graphene Enhanced Product Range for Distributors
Sept 17, 2025 19:39 HKT/SGT
|
|
|
Casa Minerals Inc Announces Advanced Ground IP Survey at the Arsenault Project
Sept 17, 2025 18:09 HKT/SGT
|
|
|
Definitive agreement to implement a joint mine plan between Los Bronces and Andina copper mines
Sept 17, 2025 18:57 JST
|
|
|
Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches 'Global Open Innovation' for U.S. Startups 
Sept 17, 2025 17:30 HKT/SGT
|
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
Sept 17, 2025 18:20 JST
|
|
|
HKTDC welcomes 2025 Policy Address
Sept 17, 2025 17:01 HKT/SGT
|
|
|
Honda Announces New Electric Motorcycle "Honda WN7" in Europe
Sept 17, 2025 17:46 JST
|
|
|
Ultraman Card Game Original Illustration of "Alien Metron" By Manga Artist Yukinobu Tatsu to be Included in the Upcoming Booster Pack Release
Sept 17, 2025 12:56 HKT/SGT
|
|
|
Professor Lin Xiang Xiong Hosts Landmark Art Exhibition and Peace Prize Ceremony in Paris
Sept 17, 2025 11:44 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
